CURALLUX, LLC – Trademark Portfolio
Entity Type: 16
CURALLUX, LLC holds 23 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 12 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 5 Nice Classification classes. Currently, 11 trademarks are registered and 1 is pending. Notable registered marks include CAP+, CURAVI, LUXANA, CAPILLUS, and CURALIGHT. The owner is based in MIAMI, FL.
1715 N.W. 82 AVENUE
MIAMI, FL 33126
Showing of trademarks Trademarks
Trademark Classifications
CURALLUX, LLC's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Apparatus for lighting, heating, steam generating, cooking, refrigerating, drying
Frequently Asked Questions
How many trademarks does CURALLUX, LLC have?
CURALLUX, LLC has 23 U.S. trademarks filed with the USPTO. Of these, 11 registered, 1 pending, 7 abandoned, 4 cancelled.
What trademark classes does CURALLUX, LLC file in?
CURALLUX, LLC files trademarks across 5 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 11 (Environmental Control), Class 21 (Housewares). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are CURALLUX, LLC's most well-known trademarks?
CURALLUX, LLC's registered trademark portfolio includes well-known marks such as CAP+, CURAVI, LUXANA, CAPILLUS, and CURALIGHT. These are among 11 currently registered trademarks in the portfolio.
What is CURALLUX, LLC's trademark registration success rate?
CURALLUX, LLC has a 50% trademark registration rate, with 11 out of 22 resolved applications resulting in successful registration. Currently, 1 application is pending review.